A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

BACKGROUND/OBJECTIVES: This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic disease-modifying antirheumatic drugs, in combination with methotrexate (MTX), in moderate-to-severe rheumatoid arthritis patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakhouri, Walid, Wang, Xiaofei, de La Torre, Inmaculada, Nicolay, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2020
Materias:
Autoimmune Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299462/
https://www.ncbi.nlm.nih.gov/pubmed/32685594
http://dx.doi.org/10.36469/jheor.2020.12273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299462/
https://www.ncbi.nlm.nih.gov/pubmed/32685594
http://dx.doi.org/10.36469/jheor.2020.12273

Ejemplares similares